Brief: Charles Steve Theofilos Files To Report Stake Of 9.99% In Akari Therapeutics PLC As Of May 31, 2024 - SEC Filing
18/06/2024 22:03
Akari Therapeutics PLC AKTX.O :
* CHARLES STEVE THEOFILOS FILES TO REPORT STAKE OF 9.99% IN
AKARI
THERAPEUTICS PLC AS OF MAY 31, 2024 - SEC FILING
Source text for Eikon: ID:n0000908834-24-000173
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics